Prosztatarák: vizsgálatok itt: Dél-Korea
62 trials · From ClinicalTrials.gov, checked 2026. november 10.. Ask the study team whether a trial fits you.
- 1/2. fázisTaking peopleFirst-Time-in-Human Study of GSK5471713 in Adults With mCRPC
- Where
- Seoul
- Életkor
- 18 év and over
- People
- 54 worldwide
- Run by
- GlaxoSmithKline
See details and how to joinNCT07332455 - 1/2. fázisTaking peopleGI-102 (CD80-IgG4 Fc-IL2v3) in Combination With Pasritamig in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) (JET-201)
- Where
- Seoul
- Életkor
- 18 év and over
- People
- 107 worldwide
- Run by
- GI Innovation, Inc.
See details and how to joinNCT07871435 - 2. fázisTaking peopleA Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate Cancer
- Where
- Seongnam-si, Seoul
- Életkor
- 18 év and over
- People
- 100 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT07287150 · EU 2025-521327-67-00 - 3. fázisTaking peopleStudy of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
- Where
- Seoul, Songpagu
- Életkor
- 18 év and over
- People
- 1310 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06136624 · EU 2023-504899-25-00 - No phaseTaking peopleAn Observational Study to Learn More About the Safety of Darolutamide in Men With Prostate Cancer in Korea
- Where
- Many Locations
- Életkor
- 19 év and over
- People
- 600
- Run by
- Bayer
See details and how to joinNCT06334120 - 1/2. fázisTaking peopleA Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors
- Where
- Seoul, Suwon
- Életkor
- 18 év and over
- People
- 345 worldwide
- Run by
- Regeneron Pharmaceuticals
See details and how to joinNCT03972657 - 1. fázisTaking peopleA Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
- Where
- Seoul
- Életkor
- 18 év and over
- People
- 460 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT06465069 · EU 2024-512927-36-00 - 1. fázisCsak meghívásosA Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring
- Where
- Seoul
- Életkor
- 18 év and over
- People
- 120 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT06788509 · EU 2024-515457-21-00 - 1. fázisCsak meghívásosA Study of ITC-6146RO in Patients With Advanced or Metastatic Cancer Who Have Failed Standard Therapy
- Where
- Seoul
- Életkor
- 18 év and over
- People
- 102
- Run by
- IntoCell, Inc
See details and how to joinNCT07423117 - 1. fázisTaking peopleA Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 In Participants With Advanced or Metastatic Prostate Cancer
- Where
- Seoul
- Életkor
- 18 év and over
- People
- 210 worldwide
- Run by
- Genentech, Inc.
See details and how to joinNCT05800665 · EU 2023-504013-68-00 - 3. fázisTaking peopleA Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)
- Where
- Daejeon, Goyang-si, HwasunGun, Seoul
- Életkor
- 18 év and over
- People
- 1203 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT07164443 · EU 2025-520927-26-00 - 3. fázisTaking peopleA Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer
- Where
- Goyang-si, Seoul
- Életkor
- 18 év and over
- People
- 800 worldwide
- Run by
- Janssen Research & Development, LLC
See details and how to joinNCT07225946 · EU 2025-522713-29-00 - 3. fázisTaking peopleA Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.
- Where
- Daegu, Goyang-si, Hwasun, Junggu, Seoul
- Életkor
- 18 év and over
- People
- 900 worldwide
- Run by
- Pfizer
See details and how to joinNCT06629779 · EU 2024-511652-40-00 - 3. fázisTaking peopleA Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
- Where
- Donggu, Hwasun Gun, Seocho-gu, Seoul, Songpagu
- Életkor
- 18 év and over
- People
- 1440 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06925737 · EU 2024-517423-40-00 - 1/2. fázisTaking peopleEIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors
- Where
- Busan, Seoul, Suwon
- Életkor
- 18 év and over
- People
- 160 worldwide
- Run by
- Eikon Therapeutics
See details and how to joinNCT07262619 · EU 2026-525248-13-00 - 2. fázisTaking peopleA Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
- Where
- Daegu, Gyeonggi-do, Seongnam, Seoul
- Életkor
- 18 év and over
- People
- 740 worldwide
- Run by
- Daiichi Sankyo
See details and how to joinNCT06172478 · EU 2023-507641-29-00 - 1. fázisTaking peopleA Study to Investigate the Safety and Tolerability of Oral INR731 Single Agent or in Combination With Androgen Receptor Pathway Inhibitor (ARPI) in Patients With Metastatic Prostate Cancer
- Where
- Seoul
- Életkor
- 18 év and over
- People
- 208 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT07570979 - 1/2. fázisTaking peopleStudy of AZD0516 as Monotherapy and in Combination in Participants With Metastatic Prostate Cancer
- Where
- Seoul
- Életkor
- 18 év to 130 év
- People
- 283 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07181161 · EU 2024-520026-11-00 - 2. fázisTaking peopleStudy of PF-07248144 in Advanced or Metastatic Solid Tumors
- Where
- Daegu, Seongnam-si, Seoul
- Életkor
- 18 év and over
- People
- 320 worldwide
- Run by
- Pfizer
See details and how to joinNCT04606446 - 3. fázisTaking peopleA Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
- Where
- Buk-gu, Goyang-si, Pusan, Seongnam, Seoul
- Életkor
- 18 év and over
- People
- 1314 worldwide
- Run by
- Merck Sharp & Dohme LLC
See details and how to joinNCT06136650 · EU 2023-504957-11-00 - 3. fázisTaking peopleA Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
- Where
- Seongnam-si, Gyeonggi-do, Seoul
- Életkor
- 18 év and over
- People
- 750 worldwide
- Run by
- Amgen
See details and how to joinNCT07213674 - 3. fázisTaking peopleAZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)
- Where
- Goyang-si, Seoul
- Életkor
- 18 év and over
- People
- 670 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07611110 - 1. fázisTaking peopleA Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
- Where
- Daejeon, Seongnam, Seoul
- Életkor
- 18 év and over
- People
- 453 worldwide
- Run by
- Pfizer
See details and how to joinNCT03460977 · EU 2023-509179-18-00 - 3. fázisTaking peopleStudy Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC
- Where
- Seoul
- Életkor
- 18 év to 100 év
- People
- 940 worldwide
- Run by
- Novartis Pharmaceuticals
See details and how to joinNCT06855277 - 3. fázisTaking peopleSaruparib in Combination With Physician's Choice of ARPI in Patients With mHSPC Previously Treated With Docetaxel or 177Lu-PSMA Therapy Without Disease Progression and PSA ≥ 0.2 ng/mL (EvoPAR-PR05)
- Where
- Daegu, Goyang-si, Seoul
- Életkor
- 18 év and over
- People
- 1330 worldwide
- Run by
- AstraZeneca
See details and how to joinNCT07711002 · EU 2026-526275-38-00